Cryofocus Medtech (Shanghai) Past Earnings Performance
Past criteria checks 0/6
Cryofocus Medtech (Shanghai) has been growing earnings at an average annual rate of 6.8%, while the Medical Equipment industry saw earnings growing at 14.1% annually. Revenues have been growing at an average rate of 16.1% per year.
Key information
6.8%
Earnings growth rate
7.3%
EPS growth rate
Medical Equipment Industry Growth | 13.7% |
Revenue growth rate | 16.1% |
Return on equity | -90.7% |
Net Margin | -256.0% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Is Cryofocus Medtech (Shanghai) (HKG:6922) Using Too Much Debt?
Sep 02We're Not Very Worried About Cryofocus Medtech (Shanghai)'s (HKG:6922) Cash Burn Rate
Jan 10Cryofocus Medtech (Shanghai) (HKG:6922) Is In A Good Position To Deliver On Growth Plans
Oct 03Companies Like Cryofocus Medtech (Shanghai) (HKG:6922) Are In A Position To Invest In Growth
May 30Revenue & Expenses Breakdown
How Cryofocus Medtech (Shanghai) makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 42 | -106 | 77 | 79 |
31 Mar 24 | 41 | -102 | 76 | 78 |
31 Dec 23 | 41 | -97 | 75 | 76 |
30 Sep 23 | 38 | -105 | 81 | 74 |
30 Jun 23 | 36 | -113 | 88 | 71 |
31 Mar 23 | 31 | -113 | 88 | 66 |
31 Dec 22 | 27 | -112 | 88 | 60 |
31 Dec 21 | 22 | -102 | 56 | 39 |
31 Dec 20 | 9 | -137 | 127 | 42 |
Quality Earnings: 6922 is currently unprofitable.
Growing Profit Margin: 6922 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6922 is unprofitable, but has reduced losses over the past 5 years at a rate of 6.8% per year.
Accelerating Growth: Unable to compare 6922's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6922 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-7.3%).
Return on Equity
High ROE: 6922 has a negative Return on Equity (-90.67%), as it is currently unprofitable.